PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 1992 February; 55(2): 126–127.
PMCID: PMC488975

Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction.

Abstract

The effect of viloxazine (150-300 mg daily for 21 days) on plasma phenytoin levels at steady state was examined in 10 epileptic patients stabilised on a fixed phenytoin dosage. After starting viloxazine treatment, plasma phenytoin concentrations increased by 37% on average (range 7-94%) from a mean value of 18.8 micrograms/ml at baseline to a mean value of 25.7 micrograms/ml during the last week of combined therapy. In four patients the rise in plasma phenytoin was associated with the development of signs of phenytoin toxicity. Discontinuation of viloxazine resulted in return of plasma phenytoin towards baseline values and disappearance of the clinical symptoms. The mechanism of interaction probably involves inhibition of phenytoin metabolism by viloxazine. Careful monitoring of plasma phenytoin levels is recommended in patients treated with phenytoin who need to be started on viloxazine therapy.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (400K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Meldrum BS, Anlezark GM, Adam HK, Greenwood DT. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology (Berl) 1982;76(3):212–217. [PubMed]
  • Edwards JG, Glen-Bott M. Does viloxazine have epileptogenic properties? J Neurol Neurosurg Psychiatry. 1984 Sep;47(9):960–964. [PMC free article] [PubMed]
  • Luchins DJ, Oliver AP, Wyatt RJ. Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia. 1984 Feb;25(1):25–32. [PubMed]
  • Pisani F, Narbone MC, Fazio A, Crisafulli P, Primerano G, D'Agostino AA, Oteri G, Di Perri R. Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia. 1984 Aug;25(4):482–485. [PubMed]
  • Pisani F, Fazio A, Oteri G, Perucca E, Russo M, Trio R, Pisani B, Di Perri R. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986 Oct;49(10):1142–1145. [PMC free article] [PubMed]
  • Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977 Jun;13(6):401–421. [PubMed]
  • Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, Trio R, Perucca E. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology (Berl) 1986;90(3):295–298. [PubMed]
  • Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet. 1982 Jan-Feb;7(1):57–84. [PubMed]
  • Perucca E, Richens A. Drug interactions with phenytoin. Drugs. 1981 Feb;21(2):120–137. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group